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Abstract 
 
Aim 
Deep inspiration breath hold (DIBH) is a method of motion management used in 
stereotactic ablative body radiotherapy (SABR) for lung tumours. An external gating 
block marker can be used as a tumour motion surrogate, however, inter-fraction gross 
target volume (GTV) displacement within DIBH occurs. This study measured this 
displacement during a reproducible breath hold regime. Additionally, factors such as 
position of the gating block marker were analysed. 	
Methods and Materials 
121 cone beam computed tomography scans (CBCTs) from 22 patients who received 
DIBH SABR were retrospectively evaluated and the magnitude of inter-fraction GTV 
displacement	was calculated for each fraction. This data was analysed to assess if any 
correlation existed between tumour displacement and variation in the gating block marker 
position on the patient, the amplitude of BH at CT, the amplitude of BH at treatment and 
the tumour location.	
The measured tumour displacement was applied to the original planning CT to evaluate 
the dosimetric effect on surrounding organs at risk (OARs) using cumulative dose volume 
histograms (DVHs). 
Results 
BH amplitude was reproducible within 0.13 cm ± 0.1 cm (mean ± standard deviation). 
The magnitude of tumour displacement within BH ranged from 0 to 1.52 cm (0.41 cm ± 
0.28 cm). Displacement in the superior-inferior (SI), anterior-posterior (AP) and left-right 
(LR) planes were 0.31cm ± 0.26 cm, 0.16 cm ± 0.18 cm and 0.07 cm ± 0.12 cm 
respectively. No statistically significant correlation was detected between tumour 
displacement within DIBH and the factors investigated. The range of variation in OAR 
dose was -7.0Gy to +3.6Gy with one statistically significant increase in OAR dose 
observed (oesophagus mean dose increasing by 0.16Gy).  
Findings 
Reproducible BH was achievable across a range of patients. Inter-fraction GTV 
displacement measured 0.41 cm ± 0.28 cm. Due to this low level of motion, the 
correction of soft tissue moves did not adversely affect OAR dose. 
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Introduction 
 
The role of SABR in early stage lung cancer management has been established as the 
gold standard treatment where the patient is medically inoperable (1) (2) (3) with local 
control rates of up to 92% being reported
 
(3). In addition SABR has benefit in the 
management of lung metastases with a local control rate of up to 80% at 1 year being 
reported (4) with minimal toxicity. 
Motion management of lung tumours is essential in delivering SABR and one method of 
motion management is DIBH. DIBH delivered SABR has been shown to be 
dosimetrically desirable, over an internal target volume (ITV) technique where tumour 
motion over all respiratory phases is accounted for (5). It was reported that lung OAR 
dose, (all dose volume constraints), were reduced by 20% using a DIBH technique 
compared to a free breathing technique. Furthermore, with the addition of DIBH a 
reduction in planning target volume (PTV) margins was possible, which lead to a 40% 
reduction in dose to OARs (5) compared to a free breathing technique. 
However, within DIBH inter-fraction variability of tumour position, relative to bony 
anatomy, occurs and this variation is observed on the daily-acquired CBCTs (6, 7).  The 
magnitude of this positional variation has been reported by a number of studies and has 
been quantified as 3.3mm (6) (7) 5.4 mm ± 2.5 mm, (8) or even 6.7mm (9) with various 
methods being used to achieve a breath hold scan.  
 
In order to account for this inter-fraction GTV displacement, image guided soft tissue 
tumour matches (away from the bony alignment) are necessary to ensure full dose 
coverage of the lesion. 
 
Within this institution DIBH SABR is facilitated by the Varian Real-Time Position 
Management (RPM) system with audio-visual coaching. This has been shown to be a 
reliable and reproducible method of motion management (10) (11). 
 
Patients are immobilised supine, arms up in a BodyFIX ® system (Elekta, Sweden), with 
a full length evacuated cushion for the patient to lie in and immobilisation is further 
assisted by a coversheet suctioned around the patients contour. 
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The RPM system utilises an external gating block, which is placed at a stable point on the 
patient’s chest (inside the suctioned cover sheet) and this is used to quantify the BH 
amplitude. This process is aided by providing the patients with video goggles showing 
live video feedback of the BH allowing the patient to monitor their own BH during 
treatment. This is reproduced for each treatment fraction and a CBCT is acquired to 
verify both bony and soft tissue anatomy.	
 
SABR patients attend for a breathing assessment appointment, prior to CT simulation, to 
ensure they can consistently achieve a reproducible BH as visualised on the RPM system 
before acquiring a planning CT scan. This appointment consists of a number of steps. The 
immobilisation device is constructed and evaluated for both stability and comfort. The 
patient is assessed for any medical requirements prior to simulation, such as analgesia. 
The patient is then given an opportunity to practice DIBH as well as coached breathing 
techniques. They then return for CT simulation 48 hours later, having had experience of 
the process and practiced the technique.	
 
This study aimed to quantify our institutions inter-fraction GTV displacement based on 
our process and evaluate if this displacement relates to minor changes in BH or the 
external gating block. A secondary aim was to evaluate the dosimetric impact of this 
tumour motion on the surrounding OARs.  
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Materials and Methods 
 
This study was approved by our institutional research committee. Data collection was in 
accordance with local protocol. 
	
	
Data	collection	and	evaluation	methods	
 
Lung tumour patients treated with DIBH SABR in our institution were retrospectively 
reviewed. A convenience sampling strategy was utilised with the following criteria: 
Included were SABR lung patients treated with a BH technique from January 1
st
 2012 to 
April 30
th
 2013 and tumour location in the lower lobe. Excluded were SABR patients 
treated with a free breathing or coached breathing technique, breath hold delivered SABR 
to abdominal lesions, lesions in the upper or middle lobes of the lung and patients not 
treated as per standard departmental protocol. Within this institution, DIBH is indicated 
over alternative motion management techniques if the tumour motion is greater than 
5mm. 
 
This yielded a study population of 22 patients, 16 males and 6 females. Their ages ranged 
from 50-85 years old with an average age of 71.59 years. Of these patients 11 had 
primary lung tumours and 11 had metastases from a variety of primaries including 
melanoma, pancreatic cancer, caecal cancer, colon cancer, colorectal cancer and rectal 
cancer. 
 
Patients were treated with between 3 and 10 fractions to a total dose ranging from 48Gy 
to 60Gy with the most common fractionation being 60Gy in 5 fractions. 
12 had right lower lobe tumours and 10 had left lower lobe tumours. 
A total of 121 fractions were delivered and a range of data (Table 1) was recorded from 
each patient who met the inclusion criteria. 
A single investigator carried out all measurements. The intra-observer variability was 
quantified, where appropriate and was noted to be 0.2cm when measuring the daily BH 
amplitude. 
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Inter-fraction variation in tumour position 
 
At each fraction a CBCT was acquired by a full rotation of the gantry in a 90 second 
acquisition time. The patient achieved this using 3-4 breatholds depending on individual 
ability. The acquired CBCT dataset was first matched to the vertebral column and then to 
the soft tissue tumour GTV in the planning scan to quantify the inter-fraction GTV 
displacement. Soft tissue moves in AP, SI and LR planes and were recorded and applied 
to correct for this displacement. 
Absolute values were generated and an overall magnitude of tumour displacement 
relative to bony anatomy was generated using the Euclidean distance formula for each 
fraction delivered. 
 
A Pearson product-moment correlation coefficient (r) was generated to investigate the 
relationship between the various factors and inter-fraction tumour displacement. The 
coefficient of determination was also generated. 
 
 
Organs at Risk evaluation 
 
The relevant OARs were deemed to be lung, spinal cord, heart, oesophagus, and chest 
wall in accordance with local protocol. 
All soft tissue moves recorded at treatment were retrospectively applied to the original 
planning scans in Eclipse™ Treatment Planning System, by moving the isocentre to the 
on-treatment position for each fraction delivered. The dose distribution was recalculated 
for each fraction, using the same monitor units. For each patient a cumulative plan was 
generated by the summation of all the delivered fractions. Cumulative DVHs were 
generated and then compared with the original approved DVH.  
The GTV was not moved in tandem with the soft tissue moves. The significance of not 
moving the GTV was evaluated on Patient 1. As well as the standard replan, a second 
replan was carried out where the GTV contour was moved in conjunction with the 
treatment beams. The new GTV was assigned a Hounsfield unit (HU) value in line with 
the original lesion as measured on the planning scan. The original lesion, if outside the 
new GTV, was assigned a HU value in keeping with surrounding lung tissue. This was 
replicated for each fraction where soft tissue moves were applied. The new plans were 
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recalculated using the original monitor units and a composite plan generated.  The 
relevant OARs were compared and only the ipsilateral lung maximum dose changed by 
1.4Gy. All other OAR dose volume constraints were unchanged. It was therefore deemed 
acceptable not to move the GTV in tandem with the beams. 
The mean, maximum and minimum dose to each OAR was reviewed as well as the 
bilateral lung volume receiving 20Gy (V20), the ipsilateral lung volume receiving 15Gy 
(V15) and the chest wall volume receiving 30Gy (V30). In addition, specific dose 
constraints used in the researchers institution were reviewed (Table 2). 
 
 
The significance of the observed changes were evaluated using a two-tailed, Type 1 t-test 
to generate a p value, with a value of <0.05 considered statistically significant. 
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Results 
 
Inter-fraction GTV displacement 
The overall magnitude of tumour displacement relative to the bony anatomy ranged from 
0 to 1.52 cm, with a mean overall magnitude of motion of 0.41 cm with a standard 
deviation of ± 0.28 cm. See Figure 1 for summary of motion per patient. The largest 
displacement was observed in the SI plane with an average motion of 0.31 cm ± 0.26 cm 
compared with 0.16 cm ± 0.18 cm in the AP plane and 0.07 cm ± 0.12 cm in the LR 
direction. 
 
The BH amplitude recorded at CT ranged from 1.2 cm to 2.8 cm with mean amplitude of 
1.7 cm within the sample population.  
The variation of BH amplitude at treatment measured on the RPM system retrospectively 
was found to range from 0 to 0.4 cm per fraction with a mean variation of 0.13 cm ± 0.1 
cm. The magnitude of tumour displacement was found not to correlate significantly with 
the variation in BH amplitude giving a correlation coefficient (r) of 0.069. 
 
Variation in the daily placement of the external gating block was observed on a number 
of the CBCTs and this ranged from 0 cm to 3.8 cm, mean discrepancy of 1.02 cm ± 0.85 
cm., no correlation was observed between this and GTV displacement..The influence of 
the block position on skin was also considered by evaluating if there was any correlation 
between tumour variability within BH and the distance the marker is placed from the 
xiphisternum. No significant relationship was observed. No correlation was observed 
between tumour location and inter-fraction displacement. 
 
See Table 3 for correlation coefficient values for each factor investigated.  
 
Organs at Risk Evaluation 
Review of the cumulative plans’ DVHs revealed a range of OAR dose variation from              
-7.0Gy to +3.6Gy. Evaluating the maximum point dose, the minimum point dose and the 
mean dose to each OAR revealed that only the chest wall and the oesophagus maximum 
and mean doses were significantly affected (Table 4). 
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The remainder of changes observed were not statistically significant. A number of 
patients having lesions treated in both lungs did not have the ipsilateral lung minus PTV 
contoured and one patient did not have oesophagus contoured. Where ipsilateral lung 
minus PTV was not contoured the patients had bilateral lung minus PTV volumes to 
allow for a more complete view of the lung dose. In the case where the oesophagus was 
not contoured the GTV was located distal to the oesophagus and it was not deemed an 
OAR.  
 
In addition the bilateral lung minus PTV V20 varied on average by -0.04% ± 0.30 % (p = 
0.545). The ipsilateral lung minus PTV V15 varied by -0.29 % ±0.75 % (p = 0.122) and 
the chest wall V30 had a mean variation of -0.67 % ±0.89 % (p = 0.002).  
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Discussion 
 
BH reproducibility and inter-fraction motion 
 
Patient ability to reproduce a stable BH amplitude on treatment was excellent. This data 
shows a mean variation of 0.13 cm ± 0.1 cm measured over 121 CBCTs and 22 patients.  
 
This compliance shows that a stable breath hold is reproducible once coaching is utilised 
and the patient has sufficient time to adapt to the technique. In our experience the initial 
breathing assessment visit aids this process for the patients.  
 
It should be noted that a single BH amplitude was selected to represent the amplitude for 
the entire CBCT, which is generally attained over 3 to 4 breaths. However, the data 
showed that compliance to BH amplitude was excellent with a mean variation of 0.13 cm 
recorded which reassures that a single BH is an adequate representation of amplitude over 
the scan acquisition. 
 
Following on from this we also found that the range of inter-fraction displacement 
observed at this institution (0.41 cm ± 0.28 cm) using a DIBH technique was in keeping 
with the published literature across a range of breath hold techniques (8, 9).  
 
The data has shown that the motion of lower lobe lung tumours can be comfortably 
controlled within 5mm. This facilitates margin reduction and significant lung sparing 
compared to an ITV technique, the dosimetric benefits to the lung have been well 
established (5, 12). 
 
Patient 8 and Patient 21 were noted to have a larger range of motion despite no larger 
variation in the measured breath hold amplitude. Patient 8 required large moves in all 
directions for one fraction (0.9 cm AP, 1.0 cm SI and 0.7 cm LR), which accounted for 
the overall larger range of motion. Discounting this single fraction this patient’s 
maximum magnitude of motion was 0.71 cm, which was similar to the remainder of the 
data. Patient 21 also had a slightly larger range of motion of 1.03 cm but again this was 
accounted for in a single fraction where a 0.9 cm SI shift was required.   
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Correlation with factors investigated 
It must also be acknowledged however, that the data also established that a level of inter-
fraction displacement does occur within BH despite the reproducibility of the BH 
achieved. 
 
This study has shown that the factors investigated show no statistically significant 
correlation with inter-fraction motion within DIBH. These factors included minor 
amplitude changes during daily treatment, positioning of the gating block relative to 
xiphisternum, minor discrepancies in the gating block positioning at daily treatment and 
tumour location within the lung. The mean variation in the daily positioning of the gating 
block was found to be 1.02cm relative to the planning CT. Clinically, this block is placed 
at a reference point on skin and a patient’s the external contour may vary from day to day, 
as is the case with all skin marks. As such the variation observed here might well be a 
combination of block placement discrepancy and skin position discrepancy.  
 
A recent study by Renming et al. (13), which was published since this research was 
carried out, also evaluated the inter-fraction variation produced with lung DIBH. They 
found a significant correlation between vertebral bone moves required and the inter-
fractional soft tissue reproducibility, which wasn’t examined in this research. This study 
had a large sample size but utilised an active breathing control system and a single breath 
hold CBCT so results may not be comparable. 
 
This lack of correlation observed could be explained by the fact that in the main there was 
little variation observed in these factors and as such they had only a modest influence on 
the inter-factional soft tissue moves required. 
 
Some trends in the data were perceived but they did not reach a level of statistical 
significance. As expected there was a weak negative correlation between the motion 
observed and the distance from the diaphragm indicating less motion in tumours located 
more superiorly in the lower lobes. 
 
This research has shown that there is no change in the stability or reproducibility of BH 
achieved in all areas of the lower lobe. This corresponds well with the data published by 
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Renming (13) who also reported no significant correlation between relative tumour 
position within the lung and inter-fractional soft tissue displacement.  
 
Organs at Risk Evaluation 
 
Overall the application of soft tissue moves had little impact on the surrounding OAR 
doses.  
 
Two OARs were affected significantly by applying soft tissue moves, with only one 
statistically significant increase in OAR dose observed which was not clinically 
significant (oesophagus mean dose increasing by 0.16Gy). The remainder of dose 
increases did not correlate significantly with soft tissue moves being applied. This 
verified that within the sample of 121 CBCTs reviewed, applying soft tissue moves 
(within the range observed of 0.41 cm ± 0.28 cm) was safe and did not adversely affect 
OAR dose. However the limitation of assessing OAR dose on the initial planning scan is 
acknowledged as OARs may displace in tandem with the tumour displacement on a daily 
CBCT. 
 
In the case of 4 patients the spinal cord maximum point dose was increased to above the 
prescribed tolerance of 18Gy. In Patients 6 and 14 this was a marginal increase from 
18.4Gy to 18.5Gy and 18.1Gy to 19.3Gy respectively. Both tumours were located close 
to the spinal cord and the physician approved cord maximum point dose was also slightly 
above the tolerance level as these were point doses to a minimal volume. Patient 4 
showed a 2.1Gy increase from 16.7Gy to 18.8Gy increasing the cord dose above the 
approved tolerance. Analysis of the OAR dose changes was limited to evaluation of the 
maximum, minimum and mean doses and three planning constraints. Review of dose 
points alone can be misleading without entire review of the DVH curve. ICRU 83 (14) 
recommends reporting of D2% as a more representative maximum dose.  
 
Conversely to these results it has been reported (15) that OARs can be clinically affected 
with statistically significant variations of up to +10% being seen in OAR max points. 
However this study matched the soft tissue tumour without a threshold and the magnitude 
of variation from bone is not reported so it is difficult to assess if these results are 
comparable. 
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This study has highlighted areas for further research. As no variable investigated has been 
found to correlate with the soft tissue displacement observed, an area for further research 
could be to evaluate the role of the vacuum cover sheet in the patient set up as this was 
not considered in this study, as well as patient related factors such as pre-existing lung 
disease. Additionally the evaluation of the inter-fraction consistency of breath hold and 
soft tissue positioning would be of interest. 
 
Conclusions 
 
This study has found that producing a reproducible BH is achievable across a range of 
patients. Our process has been shown to be a reliable and stable technique for inter-
fraction motion management in lower lobe tumours. 
It has shown that using this robust technique the magnitude of inter-fraction GTV 
displacement can easily be controlled in line with a range reported in the literature with a 
mean variation of 0.41 cm ± 0.28 cm being measured. As a result of this stringent motion 
management the application of the remainder of the soft tissue shifts has little effect on 
OAR dose. 
 
No statistical correlation was found between tumour displacement and the variables 
investigated. From this data we can conclude that within this patient cohort, this small 
level of inter-fraction displacement may be somewhat inherent in BH and thus we cannot 
reduce it by adjusting any of the factors examined in this study. Soft tissue matching 
based on CBCT image guidance has been shown to be safe and can compensate for this 
motion ensuring adequate target coverage. 
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Tables 
 
 
Table 1. Data recorded per patient 
 
 
 
 
OAR Maximum 
point dose 
Volume constraint 
Chest wall 30Gy If PTV overlaps 30Gy/30% 
Cord 18Gy N/a 
Heart 30Gy N/a 
Oesophagus 27Gy N/a 
Ipsilateral lung-PTV 60 15Gy/30% 
Bilateral Lung-PTV 60 20Gy/30% 
Table 2. OAR Dose Constraints 
 
 
 
 
 
 
 
 
Data recorded per patient 
 
 
Pre-treatment data 
BH amplitude at CT 
RPM Gating block position on patient (relative to xiphisternum)  
Tumour position relative to spine, diaphragm and chest wall 
 
Treatment data 
 
Variation in BH amplitude at treatment (relative to amplitude at CT) 
RPM Gating block position variation on patient (relative to planning 
CT: this was visible on 48 of 121 CBCTs due to field of view 
limitations. 
Soft tissue moves in AP, SI, LR directions 
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Table 3. Correlation coefficient values 
 
OAR Variation in min dose (Gy) Variation in max dose (Gy) Variation in mean dose 
(Gy) 
  Range Mean SD P 
Value 
Range Mean SD P 
Value 
Range Mean SD P 
Value 
Ipsilateral 
Lung 
-0.1 - 
0.1 
0 0.03 1 -6.8 - 
1.3 
-0.31 1.81 0.484 -0.6 - 
0.3 
-0.08 0.23 0.144 
Bilateral 
Lung 
0 0 0 n/a -6.6 - 
1.9 
-0.38 1.66 0.294 - 0.3 - 
0.4 
-0.01 0.15 0.776 
Chest Wall -0.3 - 
0.2 
-0.01 0.09 0.648 -7.0 - 
1.1 
-1.9 2.37 0.0012 -1.8 - 
0.2 
-0.3 0.46 0.006 
Heart -0.1 - 
0.1 
0 0.05 0.665 -2.5 - 
2.7 
-0.48 1.39 0.122 -0.6 - 
1.1 
-0.01 0.31 0.892 
Oesophagus -0.1 - 
0.4 
0.03 0.11 0.249 -2.2 - 
0.7 
-0.43 0.77 0.017 -1.0 - 
0.1 
0.16 0.3 0.028 
Spinal 
Cord 
-0.1 - 
0 
-0.01 0.03 0.162 -2.7 - 
3.6 
-0.07 1.3 0.795 -0.1 - 
0.3 
0 0.11 1 
Table 4. OAR Evaluation 
 
 
 
  
Factor Investigated Correlation Coefficient 
(r) 
Coefficient of 
Determination (R
2
) 
Variation in amplitude of 
BH at treatment 
0.069 0.00483 
Variation in  external 
marker position 
0.283 0.07997 
Depth of BH at planning 
CT 
0.349 0.1221 
Tumour location relevant 
to spine 
0.126 0.01582 
Tumour location relevant 
to posterior chest wall 
0.129 0.0165 
Tumour location relevant 
to lateral chest wall 
0.025 0.00061 
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Figures 
 
 
 
Figure 1.  Summary of tumour motion per patient 
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